Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

NASDAQ:STSA

Satsuma Pharmaceuticals, Inc.

Last Close

1.10

07/06 20:00

Market Cap

36.47M

Beta: 0.08

Volume Today

1.83M

Avg: 1.01M

PE Ratio

−0.58

PFCF: −0.74

Financials Not Available